Regarding the standardization of L-arginine and thiotriazoline in the model mixture by high-performance liquid chromatography
Keywords:L-arginine, thiotriazoline, HPLC, cardiovascular diseases, ischemia
Today, one of the main causes of disability and mortality in the world's population is the disease of the cardiovascular and central nervous systems. Therefore, the development of new highly effective drugs for their treatment becomes an urgent task of modern medicine and pharmacy. Promising in this direction is the creation of a new medicinal product, which combines the active donor NO – neurotransmitter amino acid L-arginine, as well as the famous domestic antioxidant – thiotriazoline. A rational dosage form – pills was chosen to create a new combined drug. Therefore, the actual and timely task is to develop methods for standardizing the active substances in the model mixture, which in future can become the basis for the analysis of the finished dosage forms of the new drug.
The purpose of the work is to develop a method for standardizing the model mixture of L-arginine and thiotriazoline in the ratio of 4:1 by HPLC method.
Materials and methods. During the research, certified substances L-arginine (manufacturer: Sigma-Aldrich, USA) and thiotriazolin (manufacturer State Enterprise “Chemical Reagents Plant” of the Scientific-Technological Complex “Institute of Single Crystals” of the National Academy of Sciences of Ukraine) were used. The research was carried out using LC-20 Prominence Shimadzu Chromatograph.
Results. First, in the laboratory, six series of model mixture of L-arginine and thiotriazoline were produced in an optimum ratio of 4:1. Continuously, the test solution and the solution of the working standard sample, were chromatographed obtaining at least three chromatograms for each solution.
It is established that the content of L-arginine in the model mixture ranges from 198.38 mg to 200.66 mg, and thiotriazoline is from 50.82 mg to 51.61 mg. According to the content of the active substances, the studied series of model mixture of L-arginine and thiotriazoline in a ratio of 4:1 correspond to the requirements of the SPF.
Conclusions. In the course of the conducted researches the method of standardization of active substances of the model mixture of L-arginine and thiotriazoline in a ratio of 4:1 by the HPLC method, which is reproducible, accurate and can be used later in the quality control of the established tablet formulation, has been developed.
Mazur, I. A., Chekman, I. S., Belenichev, I. F., Voloshin, N. A., Gorchakova, N. A., & Kucherenko, L. I. (2007). Metabolitotropnye preparaty [Metabolithotropic Drugs]. Zaporozhye. [in Russian].
Mazur, I. A., Voloshin, N. A., Chekman, I. S., Zimenkovskij, B. S., & Stec, V. R. (2005). Tiotriazolin: farmakologicheskie aspektu i klinicheskoe primenenie [Thiotriazoline: pharmacological aspects and clinical usage]. Novosti medicyny i farmacii, 160. [in Russian].
Mazur, I. A., Chekman, I. S., Belenichev, I. F., & Kucherenko, L. I. (2011). Razrabotka lekarstvennukh sredstv na osnove fiksirovannukh kombinacij s antioksidantami – perspektivnoe napravlenie sovremennoj farmakologii [The development of medicines based on fixed combinations with antioxidants is a promising area of modern pharmacology]. Farmakolohiia ta likarska toksykolohiia, 5, 199–200. [in Russian].
Mazur, І. A., Kucherenko, L. I., Belenichev, I. F., Khromylova, O. V., & Siusiuka, V. H. (patentee) (2016) Patent na vynakhid 110597 Ukraina, MPK (2015.01) A61K 31/198 (2006.01), A61K 9/00. Kombinovanyi likarskyi zasib hepatoprotektornoi, kardioprotektornoi, platsentoprotektyvnoi, tokolitychnoi i NO-mimetychnoi dii [Patent 110597, Ukraine, IPC; (2015.01) A61K 31/198 (2006.01), A61K 9/00. Combination Drug with Hepatoprotective, Cardioprotective, Placentoprotective, Tocolytic and NO-Mimetic Action]. Biulleten, 1. [in Ukrainian].
Pakhomov, V. P. (2003). Khromatohrafiia u khimiko-farmatsevtychnykh doslidzhenniakh [Chromatography in chemical and pharmaceutical studies]. Khimicheskij farmaсevticheskij zhurnal, 37(8), 55–56. [in Ukrainian].
Oiestad, E. L., Johansen, U., & Christophersen, A. S. (2007). Drug screening of preserved oral fluid by liquid chromatography-tan¬dem mass spectrometry. Clin Chem, 53(2), 300–309. doi: 10.1373/clinchem.2006.074237
Sadek, P. (2009). Rastvoriteli dlya VE’ZHKH [Solvents for HPLC]. Moscow: Binom. Laboratoriya znanij. [in Russian].
Saprykin, L. V. (2006). Praktika i metodicheskie osnovy vysokoe’fektivnoj zhydkostnoj khromatografii [Practical and methodological foundations of high-performance liquid chromatography]. Krasnodar. [in Russian].
Kucherenko, L. І., Borsuk, S. О., Mazur, І. А., Cherkovska, L. G., & Skoryna, D. Yu. (2018) Pidbir optymalnykh umov analizu sumishi L-tryptofanu z tiotryazolinom metodom vysokoefektyvnoi ridynnoi khromatohrafii [Optimization of L-tryptophan and thiotriazoline compound analysis by high-performance liquid chromatography]. Current issues in pharmacy and medicine: science and practice, 2(27), 142–147. [in Ukrainian]. doi: 10.14739/2409-2932.2018.2.133170
Kucherenko, L.І., Belenichev, I. F., Mazur, І. A., Khromylova, O. V. (2018) Optimization of L-arginine and thiotriazoline compound analysis by high-performance liquid chromatography. Zaporozhye medical journal, 6(111), 837–840. [in Ukrainian]. doi: 10.14739/2310-1210.2018.6.146760
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)